title: Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology.
abstract: BACKGROUND
  The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy.
  
  
  METHODS
  A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel (75 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) was performed as a first line regimen every 21 days.
  
  
  RESULTS
  The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1).
  
  
  CONCLUSIONS
  The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.
authors.affiliation: Department of Medical Oncology, Dr. A.Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey E-mail : drumutdemirci@gmail.com.
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Halit
authors.initials: H
authors.lastname: Karaca
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Nuriye Yildirim
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: Arife
authors.initials: A
authors.lastname: Ulas
authors.forename: Meltem
authors.initials: M
authors.lastname: Baykara
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin